ImmunoDx

Executive Summary

ImmunoDx is a commercial-stage diagnostics company specializing in advanced immunological and molecular tests for early cancer detection and monitoring. Leveraging its proprietary multi-analyte assay platform, the company profiles the immune system's response to tumors, aiming to provide more precise and actionable diagnostic information than traditional single-biomarker tests. Founded in 2008 and headquartered in Woburn, MA, ImmunoDx has raised $100 million to date, reflecting investor confidence in its approach. The company's tests are designed to improve patient outcomes by enabling earlier intervention and more informed treatment decisions, particularly in oncology where immune profiling is becoming increasingly critical. With a focus on high-sensitivity assays, ImmunoDx addresses key limitations in current cancer diagnostics, such as low specificity and inability to track dynamic immune responses. As the company scales commercial operations, it is poised to capture significant market share in the growing liquid biopsy and immune monitoring segments. The convergence of rising cancer incidence, demand for non-invasive testing, and advancements in immuno-oncology creates a favorable tailwind for ImmunoDx's growth trajectory. However, the competitive landscape includes established players and emerging startups, necessitating ongoing innovation and strategic partnerships to maintain differentiation.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation multi-analyte assay for early lung cancer detection70% success
• Q4 2026Clinical validation partnership with major academic medical center60% success
• Q1 2027FDA 510(k) clearance for immunotherapy monitoring assay50% success